Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection

Söderholm, Jonas; Waldenström, Jesper; Askarieh, Galia; Pilli, Massimo; Bochud, Pierre-Yves; Negro, Francesco; Pawlotsky, Jean-Michel; Zeuzem, Stefan; Ferrari, Carlo; Norkrans, Gunnar; Wejstål, Rune; Westin, Johan; Neumann, Avidan U.; Haagmans, Bart L.; Lindh, Magnus; Missale, Gabriele; Hellstrand, Kristoffer; Lagging, Martin
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells. Methods: Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8+ T cells. Results: Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P = 0.02) studies had lower pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26 concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL (P = 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8+ T cells (P = 0.02). Conclusions: Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection and may be associated with higher blood counts of HCV-specific CD8+ T cells.


Related Articles

  • IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. Meissner, Eric G.; Bon, Dimitra; Prokunina-Olsson, Ludmila; Tang, Wei; Masur, Henry; O'Brien, Thomas R.; Herrmann, Eva; Kottilil, Shyamasundaran; Osinusi, Anuoluwapo // Journal of Infectious Diseases;Jun2014, Vol. 209 Issue 11, p1700 

    Response to pegylated interferon-alpha and ribavirin (IFN-α/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-α–free, direct-acting antiviral (DAA) regimens is unclear. An exonic deletion allele (IFNL4-ΔG)...

  • Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. Dahlan, Yaser; Ather, Hafiz-Mughees; Al-ahmadi, Majid; Batwa, Faisal; Al-hamoudi, Waleed; Reshetnyak, Vasiliy I. // World Journal of Gastroenterology;9/21/2009, Vol. 15 Issue 35, p4429 

    AIM: To assess sustained virological response (SVR) rates in a predominantly hepatitis C virus (HCV) genotype 4 infected population. METHODS: Between 2003-2007, 240 patients who were treated for chronic hepatitis C infection at our center were included. Epidemiological data, viral genotypes, and...

  • Association of CTLA4 Polymorphisms with Sustained Response to Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Infection. Yee, Leland J.; Perez, Kevin A.; Jianming Tang; van Leeuwen, Dirk J.; Kaslow, Richard A. // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1264 

    Examines the associations of cytotoxic T lymphocyte antigen-4 single-nucleotide polymorphisms at promoter site -318 and exon-1 site 49 with clearance of hepatitis C virus after treatment with combination interferon-alpha plus ribavirin. Persistence of comparably strong associations after...

  • Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Miyazaki, Masanori; Iio, Sadaharu; Oshita, Masahide; Hagiwara, Hideki; Mita, Eiji; Inui, Yoshiaki; Hijioka, Taizo; Inada, Masami; Tamura, Shinji; Yoshihara, Harumasa; Inoue, Atsuo; Imai, Yasuharu; Miyagi, Takuya; Yoshida, Yuichi; Tatsumi, Tomohide; Kanto, Tatsuya; Kasahara, Akinori // Journal of Gastroenterology;Apr2014, Vol. 49 Issue 4, p737 

    Background: HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear. Methods: Of 547 patients with HCV...

  • Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. Murata, Kazumoto; Sugiyama, Masaya; Kimura, Tatsuji; Yoshio, Sachiyo; Kanto, Tatsuya; Kirikae, Ikue; Saito, Hiroaki; Aoki, Yoshihiko; Hiramine, Satoshi; Matsui, Teppei; Ito, Kiyoaki; Korenaga, Masaaki; Imamura, Masatoshi; Masaki, Naohiko; Mizokami, Masashi // Journal of Gastroenterology;Jan2014, Vol. 49 Issue 1, p126 

    Background: Genetic variation around interleukin-28B ( IL28B), encoding IFN-λ3, predict non-responders to pegylated interferon-α/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC). However, it remains unclear the expression and the role of IL28B itself. The aim of this study is...

  • Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy. Kadokura, Makoto; Maekawa, Shinya; Sueki, Ryota; Miura, Mika; Komase, Kazuki; Shindo, Hiroko; Amemiya, Fumitake; Uetake, Tomoyoshi; Inoue, Taisuke; Sakamoto, Minoru; Nakagawa, Mina; Sakamoto, Naoya; Watanabe, Mamoru; Enomoto, Nobuyuki // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Background and Aims: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and...

  • Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma. Miyatake, Hirokazu; Kobayashi, Yoshiyuki; Iwasaki, Yoshiaki; Nakamura, Shin-ichiro; Ohnishi, Hideki; Kuwaki, Kenji; Toshimori, Junichi; Hagihara, Hiroaki; Nouso, Kazuhiro; Yamamoto, Kazuhide // Digestive Diseases & Sciences;Apr2012, Vol. 57 Issue 4, p1092 

    Background and Aims: Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in...

  • Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).  // Virology Journal;2012, Vol. 9 Issue 1, p18 

    The article focuses on a study conducted to examine the response of standard interferon therapy in chronic Hepatitis C Virus (HCV) patients of Khyber Pakhtunkhwa (KPK) province in Pakistan. The study involved 174 patients who were given standard interferon with ribavirin after confirmation of...

  • Simeprevir for the treatment of hepatitis C virus infection. Izquierdo, Laure; Helle, François; François, Catherine; Castelain, Sandrine; Duverlie, Gilles; Brochot, Etienne // Pharmacogenomics & Personalized Medicine;Aug2014, Vol. 7, p241 

    Simeprevir (TMC435, Olysioâ„¢), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics